With licensing and collaboration now the lifeblood of the drug industry, the annual BIO-Europe get-together was focused on partnering. Nuala Moran was there.
New regulations on the registration and testing of chemicals could have some problematic knock-on effects on European R&D – but they could also bring some lucrative work the way of contract research organisations.
After the initial hype, the long haul through clinical development and the inevitable pitfalls, gene therapy is on the verge of becoming a commercial reality in Europe - ahead of the US.